INmune Bio to Unveil Video on Breakthrough Alzheimer’s Findings

INmune Bio Announces Upcoming Video on MINDFuL Trial Results

INmune Bio Inc. (NASDAQ: INMB) is set to release an informative video that delves into the additional findings from the Phase 2 MINDFuL trial, which tests the efficacy of XPro™, a groundbreaking selective soluble TNF inhibitor.

A Glimpse into the Video Presentation

This upcoming video promises to provide viewers with an extensive overview of the significant clinical insights revealed at the Alzheimer’s Association International Conference (AAIC). The presentation will explore how XPro™ was assessed in the MINDFuL study and the implications of these findings for patients, clinicians, and investors keen on the advancements in Alzheimer’s disease treatment options.

The Significance of the MINDFuL Trial

The MINDFuL trial is a pivotal double-blind, Phase 2 proof-of-concept study focused on understanding the potential of XPro™ to combat cognitive decline in early-stage Alzheimer’s disease (AD). By addressing neuroinflammation, the trial has shown compelling changes in clinical indicators such as cognition, behavior, and AD-related biomarkers. These changes indicate a consistent benefit from treatment with XPro™ over a six-month period among a specific group of patients displaying amyloid-beta pathology and at least two blood biomarkers indicative of inflammation.

Expert Insights from INmune Bio

Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio, expressed enthusiasm about the results derived from the trial. He stated, "The meaningful changes seen in a short trial are very encouraging. We are particularly excited that Dr. Sharon Cohen will present our findings at AAIC, and we look forward to sharing this valuable information broadly through our video format."

Availability of the Video

Mark your calendars! The informative video will be available at 4 PM ET on a Thursday in the near future, highlighting the rich information discussed during the AAIC session. Viewers interested in obtaining this wealth of knowledge can find it on INmune Bio’s YouTube Channel.

About INmune Bio Inc.

INmune Bio Inc. is a dynamic clinical-stage biotechnology company traded publicly on NASDAQ under the ticker INMB. The company is dedicated to innovating treatments that engage the innate immune system to combat various diseases. With three core product platforms, including a novel Dominant-Negative Tumor Necrosis Factor (DN-TNF) technology, INmune Bio is evaluating its potential for treating Mild Alzheimer’s disease, Mild Cognitive Impairment, and treatment-resistant depression with XPro™. In addition, their Natural Killer Cell Priming Platform aims to enhance the patient’s NK cell responses against cancer, currently undergoing trials in metastatic castration-resistant prostate cancer. The third platform, CORDStrom™, encompasses an allogeneic human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has shown promise in clinical settings.

Frequently Asked Questions

What is the focus of the MINDFuL trial?

The MINDFuL trial focuses on evaluating XPro™ as a treatment for slowing cognitive decline in patients with early-stage Alzheimer’s disease.

When will the video be available?

The video detailing the findings from the MINDFuL trial will be available on INmune Bio’s YouTube Channel at 4 PM ET on a Thursday following the conference.

What technology does INmune Bio utilize for its treatments?

INmune Bio employs Dominant-Negative Tumor Necrosis Factor (DN-TNF) technology to selectively neutralize soluble TNF, addressing immune dysfunction caused by chronic inflammation.

Who is leading the presentations at AAIC?

Dr. Sharon Cohen will present the data at the Alzheimer’s Association International Conference on behalf of INmune Bio.

How can I get in touch with INmune Bio?

You can reach INmune Bio by contacting David Moss, Chief Financial Officer, at (561) 710-0512 or via email at info@inmunebio.com.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.